Facebook
Twitter
LinkedIn

Media Center

FAST, Fellows & CARB-X Update | December 2020
Facebook
Twitter
LinkedIn

FAST & Fellows

Correlia Biosystems (FAST Fall 2014) a Berkeley, CA based life science startup, announced today that it has closed a $7 million Series A financing round with select global investors. Neotribe Ventures led the investment round, joined by Cota Capital, the Regents of the University of California, and others. This funding enables commercial launch of Correlia’s next-generation immunoassay platform.  This will be the first instrument planned in their larger suite of proteomics tools focused on highly efficient and automated protein measurements. Read more.

Applied Molecular Transport (FAST Spring 2014) a clinical-stage biopharmaceutical company, announced that the unique mechanism of action of AMT-101 and preclinical data supporting its potential as a treatment for ulcerative colitis (UC), and other inflammatory diseases, have been published in The Journal of Immunology. The article entitled, “A Novel Fusion of Interleukin-10 Engineered to Traffic Across Intestinal Epithelium to Treat Colitis” was published in the November 2020 online edition of The Journal of Immunology. Read more.

Fauna Bio (FAST Spring 2019) announced that co-founder and Chief Technology Officer, Linda Goodman, is a co-author on a study published in Nature as part of an international team of researchers with an effort called the Zoonomia Project. The study, which was led by the Broad Institute of MIT and Harvard and Uppsala University, analyzed and compared the whole genomes of more than 80 percent of all mammalian families, spanning almost 110 million years of evolution. The dataset includes genomes from more than 120 species that were not previously sequenced and captures mammalian diversity at an unprecedented scale. Read more.

Siolta (FAST Fall 2017) Microbiome Dx company Bio-Me and Siolta Therapeutics announced that they have entered into a collaboration and marketing agreement. Under the agreement, Siolta will provide both samples and insights into key criteria for Bio-Me to develop a rapid, detailed and comprehensive diagnostic test for infants at risk of developing allergy and asthma. Read more.